United States: Reclast Plaintiff Experts Hobbled By Daubert

Last Updated: February 16 2017
Article by Stephen J. McConnell

We have long suspected that the reason some judges are hostile to Daubert is because application of the doctrine involves so much work. Rather than merely count whether there are enough other experts out there who seem to be saying something similar to what the proffered expert would say, judges under Daubert must act as gatekeepers who scrutinize the reliability of the expert's methods. Such an effort burns up pages, time, and calories. Is it any wonder that judicial opinions that simply wave junk science along to the jury, with the usual suggestion that cross-examination and juror common sense will separate the wheat from the chaff, are pretty short, whereas those judicial opinions that really test experts under Daubert and find them wanting can be as long as a Victor Hugo novel?

Recently, Judge Hopkins of the Northern District of Alabama issued a 119-page opinion throwing out a lot of plaintiff expert opinions in Jones v. Novartis Pharmaceuticals Corp., 2017 WL 372246 (N.D. Ala. Jan. 26, 2017). We read all 119 pages, so you don't have to, though the opinion is clear and pleasant enough. It is definitely no Les Miserables. Indeed, any sense of misery vanished when we saw a heading early on in the opinion entitled "General Requirements – Judge as Gatekeeper."

The plaintiff in the Jones case alleged that she experienced an atypical femur fracture ("AFF") as a result of her treatment with a prescription osteoporosis medication, Reclast. The plaintiff proffered a variety of expert opinions. The ubiquitous Dr. Suzanne Parisian submitted the usual magnum opus about how the drug had a "causal association"with the AFFs, how the defendant was on notice of that fact, and how the defendant violated much of the Federal Register and slapped on an inadequate label, There were also two retained and two nonretained medical experts who would opine on medical causation.

The Jones court began by observing that, like Caesar's Gaul, a Daubert analysis is divided into three parts: (1) whether the expert is qualified, (2) whether the expert's methodology is reliable, and (3) whether the expert's opinion would help the jury in determining scientific or technical issues. The Jones court also emphasized that the proponent of the expert bears the burden of satisfying this test. The existence of that burden should, by itself, prevent courts from issuing perfunctory blessings of junk science. But, too often, it does not.

The court granted in part the defendant's motion to strike the testimony of plaintiff's regulatory expert, Dr. Parisian, finding both that Dr. Parisian was not qualified to offer a number of her opinions and that her methodology was unreliable. Sadly, the Jones court held that a jury might benefit from an expert explaining how FDA regulations work. Why can't the judge simply issue instructions on such strictly legal matters? Nevertheless, the Jones court did manage to prune away many of Dr. Parisian's ambitions to deliver the plaintiff's closing argument. Besides being unduly long, with paragraphs upon paragraphs simply excerpting from company documents, Dr. Parisian's expert reports are exercises in false modesty. She usually claims that she is not offering any opinion about specific causation. She also usually throws in a sentence that "There are no unsupported opinions intended to be offered regarding the 'state of mind' or 'intent' of" the defendant. That sentence is clearly a response to prior court rulings forbidding Dr. Parisian from engaging in a Vulcan mind-meld with a corporate defendant, pretending to disclose inner thoughts and beliefs and aims. But what do you suppose she means by "unsupported"? Despite the disavowal of any intention to play the Amazing Kreskin, Dr. Parisian invariably goes on to opine on exactly those things about which she coyly claims agnosticism. If she is permitted to take the witness stand, you can bet she will tell the jury about how she used to wear the quasi-military uniform of the Public Health Service, and then explain how the company had wretched quality controls, knew its product was horrible, and was responsible for the injuries alleged, biblical plagues, and all the plot-holes in Batman Begins, The Hangover, and almost any random page in the Harry Potter series.

Luckily, the Jones court was not taken in, not even a little. While in both her report and deposition Dr. Parisian disclaimed any opinion about medical causation, she wanted to testify about the "causal association" between Reclast and AFFs. The court held that she could not do so: "Despite her assertions to the contrary, Dr. Parisian has implicitly provided her own causation opinion in both her report and her deposition." But Dr. Parisian lacked both the qualifications and data to support such causation opinion. (Earlier this year, Bexis penned a post on Dr. Parisian's efforts to cobble together a "regulatory causation" line of attack against defendants.)  Further, despite the disclaimer about company knowledge and intent, it was clear from other opinions that Dr. Parisian was determined to talk about such knowledge and intent, including whether certain information put the company on notice of certain risks. The court held that she could not do so. Finally, while Dr. Parisian could opine that the label was inadequate (big surprise: we think that subject is beyond what she should be allowed to bloviate about), she could not hold forth as to whether and how a different warning might have impacted the prescribing decision of plaintiff's doctors. All in all, while we've seen decisions that clamped down even more on Dr. Parisian, Jones isn't too bad.

Now on to the causation experts. Here, the defendant did even better, as the Jones court excluded all the proffered opinions.

As is routine in the medical causation context, the Jones court separately discussed general causation (whether the drug can cause an injury) and specific causation (whether the drug caused the injury for this particular patient/plaintiff). In excluding the general causation opinion of the plaintiff's bone expert, the district court found that the Bradford Hill methodology for establishing medical causation (if you are reading this, odds are good you already have some familiarity with the Bradford Hill nine-part analysis; if you don't know them, Wikipedia will help – though, mind you, as we said in a recent post, we are hardly endorsing the use of Wikipedia in any court filing), on which the expert relied, requires as a first step the existence of an established association between a substance and a disease. Unfortunately for the plaintiff, her bone expert admitted that he could not point to a study in the peer-reviewed literature finding a statistically significant association between Reclast and AFFs. Oops. The plaintiff expert claimed to arrive at a causal association (presumably the same one that Dr. Parisian fervently wished to describe) by extrapolating from an alleged class-wide association between bisphosphonates ("BPs") and AFFs. The court rejected the attempted end-run because the expert himself was forced to admit that there are significant differences, including regarding the impact on material properties of bone, between the other class BPs, which are administered orally on a weekly or monthly basis, and Reclast, which is a once-a-year I.V. infusion. The Jones court next excluded the bone expert's specific causation opinion, (i) as unreliable in the absence of an admissible general causation opinion, and (ii) because, the court found, he inappropriately relied on Bradford Hill for specific causation when that methodology is directed to assessing general causation. The Jones court further held that to the extent the bone expert claimed to have conducted a differential diagnosis, it was admittedly only "limited," and in any case, he had failed to disclose any differential diagnosis in his expert report in violation of Federal Rule of Civil Procedure 26. (The Jones court acknowledged that what was afoot was really a differential etiology, not a differential diagnosis, but then proceeded as if it made no difference. But it does make a difference. Doctors perform differential diagnoses every day in their practice, while differential etiologies are almost always creatures of litigation.)

Plaintiff's expert statistician opined that Reclast clinical trial data provides "evidence of causality" based on a reanalysis of such data that he conducted. The Jones court found that the statistician was not qualified to perform his reanalysis because he lacked a medical degree and expertise on BPs or AFFs. The court also rejected the reliability of the expert's methodology in a number of respects, including (i) his selection of a supposed background rate for AFFs, (ii) his attempt, without the necessary qualifications, to reclassify events reported in a study as AFFs, (iii) his inclusion of an event that plainly failed to meet the AFF definition, (iv) his comparison of a point estimate to a lower bound confidence interval, and (v) his use of a one-tailed test rather than a two-tailed test to calculate a confidence interval. This part of the Daubert analysis involved some heavy-lifting, and the Jones court's reasoning is muscular.

Finally, the Jones court completely excluded the proffered opinions of two nonretained experts, doctors who had treated the plaintiff's fracture. The court held that the two doctors were unqualified to opine on causation and, in any event, they had failed to rule out alternative causes of the AFF. Interestingly, the Jones court also held that, absent a general causation opinion, a so-called differential diagnosis is inherently unreliable.

So after 119 pages of judicial reasoning, we end up with a healthily scaled-back Dr. Parisian and a quartet of medical experts excluded entirely. It was worth the read.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.